Gilead Sciences Trading Volume Plummets 74 Percent to 124th Place Despite New HIV Drug Approval

On June 23, 2025, Gilead Sciences (GILD) experienced a significant drop in trading volume, with a total of $621 million in shares traded, marking a 74.36% decrease from the previous day. This decline placed Gilead at the 124th position in terms of trading volume for the day. The stock price of Gilead Sciences also decreased by 2.13%.

Gilead Sciences recently received FDA approval for its new HIV prevention drug, Yeztugo. This approval is a significant milestone for the company, as it expands its portfolio of HIV treatment options. Yeztugo is designed to be a pre-exposure prophylaxis (PrEP) for HIV, providing an additional layer of protection for individuals at risk of contracting the virus.

This approval comes at a time when the demand for effective HIV prevention methods is on the rise. With the introduction of Yeztugo, Gilead Sciences is poised to strengthen its position in the HIV treatment market, potentially driving future growth and innovation in this critical area of healthcare.